Human Viral Oncoproteins and Ubiquitin–Proteasome System

Zahra Rafiei Atani; Sareh Sadat Hosseini; Hossein Goudarzi; Ebrahim Faghihloo

doi:10.1055/s-0044-1790210

Global Medical Genetics, Inhaltsverzeichnis

CC BY 4.0 · Glob Med Genet 2024; 11(04): 285-296
DOI: 10.1055/s-0044-1790210

Review Article

Human Viral Oncoproteins and Ubiquitin–Proteasome System

Autor*innen

Zahra Rafiei Atani

¹Department of Microbiology, Faculty of Medicine, Shahed University, Tehran, Iran

²Student Research Committee, Faculty of Medicine, Shahed University, Tehran, Iran
Sareh Sadat Hosseini

³Reference Health Laboratory, Ministry of Health and Medical Education, Tehran, Iran
Hossein Goudarzi

⁴Department of Microbiology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
Ebrahim Faghihloo

⁴Department of Microbiology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Abstract

Some human cancers worldwide may be related to human tumor viruses. Knowing, controlling, and managing the viruses that cause cancers remain a problem. Also, tumor viruses use ubiquitin–proteasome system (UPS) that can alter host cellular processes through UPS. Human tumor viruses cause persistent infections, due to their ability to infect their host cells without killing them. Tumor viruses such as Epstein–Barr virus, hepatitis C virus, hepatitis B virus, human papillomaviruses, human T cell leukemia virus, Kaposi's sarcoma-associated herpesvirus, and Merkel cell polyomavirus are associated with human malignancies. They interfere with the regulation of cell cycle and control of apoptosis, which are important for cellular functions. These viral oncoproteins bind directly or indirectly to the components of UPS, modifying cellular pathways and suppressor proteins like p53 and pRb. They can also cause progression of malignancy. In this review, we focused on how viral oncoproteins bind to the components of the UPS and how these interactions induce the degradation of cellular proteins for their survival.

Keywords

proteasome - UPS - ubiquitin - oncoprotein - tumor virus

Volltext

Referenzen

References
1 Mesri EA, Feitelson MA, Munger K. Human viral oncogenesis: a cancer hallmarks analysis. Cell Host Microbe 2014; 15 (03) 266-282
2 Thomas M, Banks L. Viral oncoproteins and ubiquitination: accessing a cellular toolbox for modifying protein function. FEBS J 2017; 284 (19) 3168-3170
3 Ravid T, Hochstrasser M. Diversity of degradation signals in the ubiquitin-proteasome system. Nat Rev Mol Cell Biol 2008; 9 (09) 679-690
4 L Aravind EVK. The U box is a modified RING finger - a common domain in ubiquitination. Curr Biol 2000; 10 (04) 132-134
5 Jackson PK, Eldridge AG, Freed E. et al. The lore of the RINGs: substrate recognition and catalysis by ubiquitin ligases. Trends Cell Biol 2000; 10 (10) 429-439
6 Koegl M, Hoppe T, Schlenker S, Ulrich HD, Mayer TU, Jentsch S. A novel ubiquitination factor, E4, is involved in multiubiquitin chain assembly. Cell 1999; 96 (05) 635-644
7 Ortolan TG, Tongaonkar P, Lambertson D, Chen L, Schauber C, Madura K. The DNA repair protein rad23 is a negative regulator of multi-ubiquitin chain assembly. Nat Cell Biol 2000; 2 (09) 601-608
8 Blanchette P, Branton PE. Manipulation of the ubiquitin-proteasome pathway by small DNA tumor viruses. Virology 2009; 384 (02) 317-323
9 Levitskaya J, Sharipo A, Leonchiks A, Ciechanover A, Masucci MG. Inhibition of ubiquitin/proteasome-dependent protein degradation by the Gly-Ala repeat domain of the Epstein-Barr virus nuclear antigen 1. Proc Natl Acad Sci U S A 1997; 94 (23) 12616-12621
10 Dantuma NP, Heessen S, Lindsten K, Jellne M, Masucci MG. Inhibition of proteasomal degradation by the Gly-Ala repeat of Epstein-Barr virus is influenced by the length of the repeat and the strength of the degradation signal. Proc Natl Acad Sci U S A 2000; 97 (15) 8381-8385
11 Holowaty MN, Zeghouf M, Wu H. et al. Protein profiling with Epstein-Barr nuclear antigen-1 reveals an interaction with the herpesvirus-associated ubiquitin-specific protease HAUSP/USP7. J Biol Chem 2003; 278 (32) 29987-29994
12 Quinn LL, Williams LR, White C, Forrest C, Zuo J, Rowe M. The missing link in Epstein-Barr virus immune evasion: the BDLF3 gene induces ubiquitination and downregulation of major histocompatibility complex class I (MHC-I) and MHC-II. J Virol 2015; 90 (01) 356-367
13 Full F, Hahn AS, Großkopf AK, Ensser A. Gammaherpesviral tegument proteins, PML-nuclear bodies and the ubiquitin-proteasome system. Viruses 2017; 9 (10) 308
14 Allday MJ, Farrell PJ. Epstein-Barr virus nuclear antigen EBNA3C/6 expression maintains the level of latent membrane protein 1 in G1-arrested cells. J Virol 1994; 68 (06) 3491-3498
15 Maruo S, Zhao B, Johannsen E, Kieff E, Zou J, Takada K. Epstein-Barr virus nuclear antigens 3C and 3A maintain lymphoblastoid cell growth by repressing p16INK4A and p14ARF expression. Proc Natl Acad Sci U S A 2011; 108 (05) 1919-1924
16 Banerjee S, Lu J, Cai Q, Sun Z, Jha HC, Robertson ES. EBNA3C augments Pim-1 mediated phosphorylation and degradation of p21 to promote B-cell proliferation. PLoS Pathog 2014; 10 (08) e1004304
17 Knight JS, Sharma N, Robertson ES. SCFSkp2 complex targeted by Epstein-Barr virus essential nuclear antigen. Mol Cell Biol 2005; 25 (05) 1749-1763
18 Touitou R, O'Nions J, Heaney J, Allday MJ. Epstein-Barr virus EBNA3 proteins bind to the C8/alpha7 subunit of the 20S proteasome and are degraded by 20S proteasomes in vitro, but are very stable in latently infected B cells. J Gen Virol 2005; 86 (Pt 5): 1269-1277
19 Zancai P, Dal Col J, Piccinin S. et al. Retinoic acid stabilizes p27Kip1 in EBV-immortalized lymphoblastoid B cell lines through enhanced proteasome-dependent degradation of the p45Skp2 and Cks1 proteins. Oncogene 2005; 24 (15) 2483-2494
20 Pei Y, Banerjee S, Jha HC, Sun Z, Robertson ES. An essential EBV latent antigen 3C binds Bcl6 for targeted degradation and cell proliferation. PLoS Pathog 2017; 13 (07) e1006500
21 Haupt Y, Maya R, Kazaz A, Oren M. Mdm2 promotes the rapid degradation of p53. Nature 1997; 387 (6630): 296-299
22 Eliopoulos AG, Caamano JH, Flavell J. et al. Epstein-Barr virus-encoded latent infection membrane protein 1 regulates the processing of p100 NF-kappaB2 to p52 via an IKKgamma/NEMO-independent signalling pathway. Oncogene 2003; 22 (48) 7557-7569
23 Harada S, Kieff E. Epstein-Barr virus nuclear protein LP stimulates EBNA-2 acidic domain-mediated transcriptional activation. J Virol 1997; 71 (09) 6611-6618
24 Kim MJ, Yoo JY. Inhibition of hepatitis C virus replication by IFN-mediated ISGylation of HCV-NS5A. J Immunol 2010; 185 (07) 4311-4318
25 Hou W, Tian Q, Zheng J, Bonkovsky HL. Zinc mesoporphyrin induces rapid proteasomal degradation of hepatitis C nonstructural 5A protein in human hepatoma cells. Gastroenterology 2010; 138 (05) 1909-1919
26 Gao L, Tu H, Shi ST. et al. Interaction with a ubiquitin-like protein enhances the ubiquitination and degradation of hepatitis C virus RNA-dependent RNA polymerase. J Virol 2003; 77 (07) 4149-4159
27 Pavio N, Taylor DR, Lai MM. Detection of a novel unglycosylated form of hepatitis C virus E2 envelope protein that is located in the cytosol and interacts with PKR. J Virol 2002; 76 (03) 1265-1272
28 Varaklioti A, Vassilaki N, Georgopoulou U, Mavromara P. Alternate translation occurs within the core coding region of the hepatitis C viral genome. J Biol Chem 2002; 277 (20) 17713-17721
29 Yuksek K, Chen WL, Chien D, Ou JH. Ubiquitin-independent degradation of hepatitis C virus F protein. J Virol 2009; 83 (02) 612-621
30 Shoji I. Roles of the two distinct proteasome pathways in hepatitis C virus infection. World J Virol 2012; 1 (02) 44-50
31 Suzuki R, Moriishi K, Fukuda K. et al. Proteasomal turnover of hepatitis C virus core protein is regulated by two distinct mechanisms: a ubiquitin-dependent mechanism and a ubiquitin-independent but PA28gamma-dependent mechanism. J Virol 2009; 83 (05) 2389-2392
32 Shirakura M, Murakami K, Ichimura T. et al. E6AP ubiquitin ligase mediates ubiquitylation and degradation of hepatitis C virus core protein. J Virol 2007; 81 (03) 1174-1185
33 Ikeda F, Deribe YL, Skånland SS. et al. SHARPIN forms a linear ubiquitin ligase complex regulating NF-κB activity and apoptosis. Nature 2011; 471 (7340): 637-641
34 Tokunaga F, Nakagawa T, Nakahara M. et al. SHARPIN is a component of the NF-κB-activating linear ubiquitin chain assembly complex. Nature 2011; 471 (7340): 633-636
35 Dandri M, Locarnini S. New insight in the pathobiology of hepatitis B virus infection. Gut 2012; 61 (Suppl. 01) i6-i17
36 Yan H, Zhong G, Xu G. et al. Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus. eLife 2012; 1: e00049
37 Qian G, Jin F, Chang L, Yang Y, Peng H, Duan C. NIRF, a novel ubiquitin ligase, interacts with hepatitis B virus core protein and promotes its degradation. Biotechnol Lett 2012; 34 (01) 29-36
38 Wang Z, Ni J, Li J, Shi B, Xu Y, Yuan Z. Inhibition of hepatitis B virus replication by cIAP2 involves accelerating the ubiquitin-proteasome-mediated destruction of polymerase. J Virol 2011; 85 (21) 11457-11467
39 Leupin O, Bontron S, Schaeffer C, Strubin M. Hepatitis B virus X protein stimulates viral genome replication via a DDB1-dependent pathway distinct from that leading to cell death. J Virol 2005; 79 (07) 4238-4245
40 Kalra N, Kumar V. The X protein of hepatitis B virus binds to the F box protein Skp2 and inhibits the ubiquitination and proteasomal degradation of c-Myc. FEBS Lett 2006; 580 (02) 431-436
41 Minor MM, Slagle BL. Hepatitis B virus HBx protein interactions with the ubiquitin proteasome system. Viruses 2014; 6 (11) 4683-4702
42 Kong F, You H, Kong D, Zheng K, Tang R. The interaction of hepatitis B virus with the ubiquitin proteasome system in viral replication and associated pathogenesis. Virol J 2019; 16 (01) 73
43 Sharma P, Nag A. CUL4A ubiquitin ligase: a promising drug target for cancer and other human diseases. Open Biol 2014; 4 (02) 130217
44 Hodgson AJ, Hyser JM, Keasler VV, Cang Y, Slagle BL. Hepatitis B virus regulatory HBx protein binding to DDB1 is required but is not sufficient for maximal HBV replication. Virology 2012; 426 (01) 73-82
45 Huang J, Kwong J, Sun EC, Liang TJ. roteasome complex as a potential Üellular target of hepatitis B virus X rotein. J Virol 1996; Aug; 70 (08) 5582-5591
46 King AMQ, Adams MJ, Carstens EB, Lefkowitz EJ. Virus taxonomy: classification and nomenclature of viruses. Ninth Report of the International Committee on Taxonomy of Viruses. Elsevier; Amsterdam: 2012
47 López-Bueno A, Mavian C, Labella AM. et al. Concurrence of iridovirus, polyomavirus, and a unique member of a new group of fish papillomaviruses in lymphocystis disease-affected gilthead sea bream. J Virol 2016; 90 (19) 8768-8779
48 Pietsch EC, Murphy ME. Low risk HPV-E6 traps p53 in the cytoplasm and induces p53-dependent apoptosis. Cancer Biol Ther 2008; 7 (12) 1916-1918
49 Bernard X, Robinson P, Nominé Y. et al. Proteasomal degradation of p53 by human papillomavirus E6 oncoprotein relies on the structural integrity of p53 core domain. PLoS One 2011; 6 (10) e25981
50 de Villiers EM, Fauquet C, Broker TR, Bernard HU, zur Hausen H. Classification of papillomaviruses. Virology 2004; 324 (01) 17-27
51 Chaturvedi AK, Engels EA, Anderson WF, Gillison ML. Incidence trends for human papillomavirus-related and -unrelated oral squamous cell carcinomas in the United States. J Clin Oncol 2008; 26 (04) 612-619
52 Einstein MH, Schiller JT, Viscidi RP. et al. Clinician's guide to human papillomavirus immunology: knowns and unknowns. Lancet Infect Dis 2009; 9 (06) 347-356
53 Scheffner M, Whitaker NJ. Human papillomavirus-induced carcinogenesis and the ubiquitin-proteasome system. Semin Cancer Biol 2003; 13 (01) 59-67
54 zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2002; 2 (05) 342-350
55 Scheffner M, Huibregtse JM, Vierstra RD, Howley PM. The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell 1993; 75 (03) 495-505
56 Grossman SR, Mora R, Laimins LA. Intracellular localization and DNA-binding properties of human papillomavirus type 18 E6 protein expressed with a baculovirus vector. J Virol 1989; 63 (01) 366-374
57 Schwarz SE, Rosa JL, Scheffner M. Characterization of human hect domain family members and their interaction with UbcH5 and UbcH7. J Biol Chem 1998; 273 (20) 12148-12154
58 White EA, Sowa ME, Tan MJ. et al. Systematic identification of interactions between host cell proteins and E7 oncoproteins from diverse human papillomaviruses. Proc Natl Acad Sci U S A 2012; 109 (05) E260-E267
59 Oh KJ, Kalinina A, Wang J, Nakayama K, Nakayama KI, Bagchi S. The papillomavirus E7 oncoprotein is ubiquitinated by UbcH7 and Cullin 1- and Skp2-containing E3 ligase. J Virol 2004; 78 (10) 5338-5346
60 Tedesco D, Lukas J, Reed SI. The pRb-related protein p130 is regulated by phosphorylation-dependent proteolysis via the protein-ubiquitin ligase SCF(Skp2). Genes Dev 2002; 16 (22) 2946-2957
61 Wang J, Sampath A, Raychaudhuri P, Bagchi S. Both Rb and E7 are regulated by the ubiquitin proteasome pathway in HPV-containing cervical tumor cells. Oncogene 2001; 20 (34) 4740-4749
62 Berezutskaya E, Bagchi S. The human papillomavirus E7 oncoprotein functionally interacts with the S4 subunit of the 26 S proteasome. J Biol Chem 1997; 272 (48) 30135-30140
63 Menon S, Rossi R, Benoy I, Bogers JP, van den Broeck D. Human papilloma virus infection in HIV-infected women in Belgium: implications for prophylactic vaccines within this subpopulation. Eur J Cancer Prev 2018; 27 (01) 46-53
64 Boyer SN, Wazer DE, Band V. E7 protein of human papilloma virus-16 induces degradation of retinoblastoma protein through the ubiquitin-proteasome pathway. Cancer Res 1996; 56 (20) 4620-4624
65 Oh ST, Longworth MS, Laimins LA. Roles of the E6 and E7 proteins in the life cycle of low-risk human papillomavirus type 11. J Virol 2004; 78 (05) 2620-2626
66 Bhatia S, Afanasiev O, Nghiem P. Immunobiology of Merkel cell carcinoma: implications for immunotherapy of a polyomavirus-associated cancer. Curr Oncol Rep 2011; 13 (06) 488-497
67 Chang Y, Moore PS. Merkel cell carcinoma: a virus-induced human cancer. Annu Rev Pathol 2012; 7: 123-144
68 Kwun HJ, Wendzicki JA, Shuda Y, Moore PS, Chang Y. Merkel cell polyomavirus small T antigen induces genome instability by E3 ubiquitin ligase targeting. Oncogene 2017; 36 (49) 6784-6792
69 Borchert S, Czech-Sioli M, Neumann F. et al. High-affinity Rb binding, p53 inhibition, subcellular localization, and transformation by wild-type or tumor-derived shortened Merkel cell polyomavirus large T antigens. J Virol 2014; 88 (06) 3144-3160
70 Pietropaolo V, Prezioso C, Moens U. Merkel cell polyomavirus and Merkel cell carcinoma. Cancers (Basel) 2020; 12 (07) 1774
71 Dye KN, Welcker M, Clurman BE, Roman A, Galloway DA. Merkel cell polyomavirus tumor antigens expressed in Merkel cell carcinoma function independently of the ubiquitin ligases Fbw7 and β-TrCP. PLoS Pathog 2019; 15 (01) e1007543
72 Wendzicki JA. Comparative analyses of tumorigenic mechanisms of Merkel cell polyomavirus T antigens. University of Pittsburgh; 2019
73 Antman K, Chang Y. Kaposi's sarcoma. N Engl J Med 2000; 342 (14) 1027-1038
74 Mesri EA, Cesarman E, Boshoff C. Kaposi's sarcoma and its associated herpesvirus. Nat Rev Cancer 2010; 10 (10) 707-719
75 Stürzl M, Zietz C, Monini P, Ensoli B. Human herpesvirus-8 and Kaposi's sarcoma: relationship with the multistep concept of tumorigenesis. Adv Cancer Res 2001; 81: 125-159
76 Chang Y, Cesarman E, Pessin MS. et al. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science 1994; 266 (5192): 1865-1869
77 Boshoff C, Endo Y, Collins PD. et al. Angiogenic and HIV-inhibitory functions of KSHV-encoded chemokines. Science 1997; 278 (5336): 290-294
78 Ganem D. KSHV and Kaposi's sarcoma: the end of the beginning?. Cell 1997; 91 (02) 157-160
79 Kaul R, Verma SC, Robertson ES. Protein complexes associated with the Kaposi's sarcoma-associated herpesvirus-encoded LANA. Virology 2007; 364 (02) 317-329
80 Sarid R, Wiezorek JS, Moore PS, Chang Y. Characterization and cell cycle regulation of the major Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) latent genes and their promoter. J Virol 1999; 73 (02) 1438-1446
81 Borah S, Verma SC, Robertson ES. ORF73 of herpesvirus saimiri, a viral homolog of Kaposi's sarcoma-associated herpesvirus, modulates the two cellular tumor suppressor proteins p53 and pRb. J Virol 2004; 78 (19) 10336-10347
82 Cai Q, Verma SC, Lu J, Robertson ES. Molecular biology of Kaposi's sarcoma-associated herpesvirus and related oncogenesis. Adv Virus Res 2010; 78: 87-142
83 Cathomas G. Kaposi's sarcoma-associated herpesvirus (KSHV)/human herpesvirus 8 (HHV-8) as a tumour virus. Herpes 2003; 10 (03) 72-77
84 Suzuki T, Isobe T, Kitagawa M, Ueda K. Kaposi's sarcoma-associated herpesvirus-encoded LANA positively affects on ubiquitylation of p53. Biochem Biophys Res Commun 2010; 403 (02) 194-197
85 Cai Q, Xiao B, Si H. et al. Kaposi's sarcoma herpesvirus upregulates Aurora A expression to promote p53 phosphorylation and ubiquitylation. PLoS Pathog 2012; 8 (03) e1002566
86 Gallo RC. History of the discoveries of the first human retroviruses: HTLV-1 and HTLV-2. Oncogene 2005; 24 (39) 5926-5930
87 Gonçalves DU, Proietti FA, Ribas JG. et al. Epidemiology, treatment, and prevention of human T-cell leukemia virus type 1-associated diseases. Clin Microbiol Rev 2010; 23 (03) 577-589
88 Manns A, Blattner WA. The epidemiology of the human T-cell lymphotrophic virus type I and type II: etiologic role in human disease. Transfusion 1991; 31 (01) 67-75
89 Mahieux R, Gessain A. The human HTLV-3 and HTLV-4 retroviruses: new members of the HTLV family. Pathol Biol (Paris) 2009; 57 (02) 161-166
90 Poiesz BJ, Ruscetti FW, Gazdar AF, Bunn PA, Minna JD, Gallo RC. Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc Natl Acad Sci U S A 1980; 77 (12) 7415-7419
91 de Castro-Amarante MF, Pise-Masison CA, McKinnon K. et al. Human T cell leukemia virus type 1 infection of the three monocyte subsets contributes to viral burden in humans. J Virol 2015; 90 (05) 2195-2207
92 Franchini G, Mann DL, Popovic M, Zicht RR, Gallo RC, Wong-Staal F. HTLV-I infection of T and B cells of a patient with adult T-cell leukemia-lymphoma (ATLL) and transmission of HTLV-I from B cells to normal T cells. Leuk Res 1985; 9 (11) 1305-1314
93 Matsuoka M, Jeang KT. Human T-cell leukaemia virus type 1 (HTLV-1) infectivity and cellular transformation. Nat Rev Cancer 2007; 7 (04) 270-280
94 Richardson JH, Edwards AJ, Cruickshank JK, Rudge P, Dalgleish AG. In vivo cellular tropism of human T-cell leukemia virus type 1. J Virol 1990; 64 (11) 5682-5687
95 Taylor GP, Matsuoka M. Natural history of adult T-cell leukemia/lymphoma and approaches to therapy. Oncogene 2005; 24 (39) 6047-6057
96 Giam CZ, Semmes OJ. HTLV-1 infection and adult T-cell leukemia/lymphoma-a tale of two proteins: Tax and HBZ. Viruses 2016; 8 (06) 161
97 Kajiyama W, Kashiwagi S, Ikematsu H, Hayashi J, Nomura H, Okochi K. Intrafamilial transmission of adult T cell leukemia virus. J Infect Dis 1986; 154 (05) 851-857
98 Kaplan JE, Khabbaz RF, Murphy EL. et al; The Retrovirus Epidemiology Donor Study Group. Male-to-female transmission of human T-cell lymphotropic virus types I and II: association with viral load. J Acquir Immune Defic Syndr Hum Retrovirol 1996; 12 (02) 193-201
99 Murphy EL, Figueroa JP, Gibbs WN. et al. Sexual transmission of human T-lymphotropic virus type I (HTLV-I). Ann Intern Med 1989; 111 (07) 555-560
100 Ureta-Vidal A, Angelin-Duclos C, Tortevoye P. et al. Mother-to-child transmission of human T-cell-leukemia/lymphoma virus type I: implication of high antiviral antibody titer and high proviral load in carrier mothers. Int J Cancer 1999; 82 (06) 832-836
101 Marriott SJ, Semmes OJ. Impact of HTLV-I Tax on cell cycle progression and the cellular DNA damage repair response. Oncogene 2005; 24 (39) 5986-5995
102 Pise-Masison CA, Radonovich M, Dohoney K. et al. Gene expression profiling of ATL patients: compilation of disease-related genes and evidence for TCF4 involvement in BIRC5 gene expression and cell viability. Blood 2009; 113 (17) 4016-4026
103 Chiari E, Lamsoul I, Lodewick J, Chopin C, Bex F, Pique C. Stable ubiquitination of human T-cell leukemia virus type 1 tax is required for proteasome binding. J Virol 2004; 78 (21) 11823-11832
104 Kehn K, Fuente CdeL, Strouss K. et al. The HTLV-I Tax oncoprotein targets the retinoblastoma protein for proteasomal degradation. Oncogene 2005; 24 (04) 525-540